[1] Memon N, Weinberger BI, Hegyi T, et al. Inherited disorders of bilirubin clearance. Pediatr Res, 2016,79(3):378-386.
[2] Wagner KH, Shiels RG, Lang CA, et al. Diagnostic criteria and contributors to gilbert's syndrome. Crit Rev Clin Lab Sci, 2018,55(2):129-139.
[3] Kamal S, Abdelhakam S, Ghoraba D, et al. The frequency, clinical course, and health related quality of life in adults with gilbert's syndrome: A longitudinal study. BMC Gastroenterol, 2019,19(1):22.
[4] Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: New insights into molecular mechanisms and consequences. Gastroenterology, 2014,146(7):1625-1638.
[5] Huang MJ, Chen YC, Huang YY, et al. Effect of udp-glucuronosyltransferase 1a1 activity on risk for developing gilbert's syndrome. Kaohsiung J Med Sci, 2019, 35(7):432-439.
[6] Gilbert A, Lereboullet P. La La cholamae simple familiale. Sem Med, 1901,21:241–248
[7] Mooij MG, Schwarz UI, de Koning BA, et al. Ontogeny of human hepatic and intestinal transporter gene expression during childhood: Age matters. Drug Metab Dispos, 2014,42(8):1268-1274.
[8] King D, Armstrong MJ. Overview of gilbert's syndrome. Drug Ther Bull, 2019,57(2):27-31.
[9] Muraca M, Fevery J. Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver . Gastroenterology, 1984, 87(2):308-313.
[10] Sugatani J, Mizushima K, Osabe M, et al. Transcriptional regulation of human ugt1a1 gene expression through distal and proximal promoter motifs: Implication of defects in the ugt1a1 gene promoter. Naunyn Schmiedebergs Arch Pharmacol, 2008,377(4-6):597-605.
[11] Maruo Y, Nakahara S, Yanagi T, et al. Genotype of ugt1a1 and phenotype correlation between crigler-najjar syndrome type ii and gilbert syndrome. J Gastroenterol Hepatol, 2016,31(2):403-408.
[12] Sun L, Li M, Zhang L, et al. Differences in ugt1a1 gene mutations and pathological liver changes between chinese patients with gilbert syndrome and crigler-najjar syndrome type ii. Medicine (Baltimore), 2017,96(45):e8620.
[13] Hamoud AR, Weaver L, Stec DE, et al. Bilirubin in the liver-gut signaling axis. Trends Endocrinol Metab, 2018,29(3):140-150.
[14] Stec DE, John K, Trabbic CJ, et al. Bilirubin binding to pparalpha inhibits lipid accumulation. PLoS One, 2016,11(4):0153427.
[15] Inoguchi T, Sasaki S, Kobayashi K, et al. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA, 2007,298(12):1398-1400.
[16] Vitek L, Bellarosa C, Tiribelli C. Induction of mild hyperbilirubinemia: Hype or real therapeutic opportunity? Clin Pharmacol Ther, 2019,106(3):568-575.
[17] Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: A meta-analysis of published studies. Exp Biol Med (Maywood), 2003,228(5):568-571.
[18] Maruhashi T, Soga J, Fujimura N, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in gilbert syndrome. Circulation, 2012,126(5):598-603.
[19] Nano J, Muka T, Cepeda M, et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes: A systematic review and meta-analysis of observational evidence. Diabetes Metab, 2016,42(6):389-397.
[20] Salomone F, Li Volti G, Rosso C, et al. Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis. J Gastroenterol Hepatol, 2013,28(7):1202-1208.
[21] Landerer S, Kalthoff S, Paulusch S, et al. A Gilbert syndrome-associated haplotype protects against fatty liver disease in humanized transgenic mice. Sci Rep, 2020,10(1):8689.
[22] Hjelkrem M, Morales A, Williams CD, et al. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (nash). Aliment Pharmacol Ther, 2012,35(12):1416-1423.
[23] Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome) . Best Pract Res Clin Gastroenterol, 2010,24(5):555-571.
[24] Hahn RZ, Antunes MV, Verza SG, et al. Pharmacokinetic and pharmacogenetic markers of irinotecan toxicity. Curr Med Chem, 2019,26(12):2085-2107.
[25] Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of udp glucuronosyltransferases by atazanavir and other hiv protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos, 2005,33(11):1729-1739.
[26] Longhi MS, Vuerich M, Kalbasi A, et al. Bilirubin suppresses th17 immunity in colitis by upregulating cd39. JCI Insight, 2017,2(9):92791.
[27] Idelman G, Smith DLH, Zucker SD. Bilirubin inhibits the up-regulation of inducible nitric oxide synthase by scavenging reactive oxygen species generated by the toll-like receptor 4-dependent activation of nadph oxidase. Redox Biol, 2015,5(398-408). |
